Business Wire

FOURKITES

9.11.2022 09:01:33 CET | Business Wire | Press release

Share
FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience

Today, leading supply chain visibility company FourKites announced a partnership with Sony Network Communications Europe. The partnership will integrate data from Visilion — Sony’s real-time cargo and asset tracking solution — with FourKites’ real-time, end-to-end supply chain visibility platform. This collaboration will help enterprise customers solve their most complex use cases. Now, customers will be able to view FourKites’ real-time data for shipments in transit and in the yard, together with Visilion’s granular real-time data on cargo location and condition to provide best-in-class estimated times of arrival (ETAs) and enhanced end-customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience (Graphic: Business Wire)

Faced with ongoing global supply chain disruptions — including port congestion, port and rail strikes, global conflicts and more — businesses need more meaningful insights to mitigate preventable delays and damage, and to keep goods moving to their final destinations. Real-time visibility and actionable analytics regarding the location, temperature and status of shipments is critical, particularly for those in the Consumer Packaged Goods, Food & Beverage and Pharmaceutical industries, who ship products that require specific in-transit conditions to maintain quality.

“Businesses today require more high-quality, real-time supply chain data,” said Nimesh Patel, vice president of global alliances and partnerships at FourKites. “The Visilion solution from Sony provides an extra layer of granular data about the contents of containers and status of sensitive and/or temperature-controlled shipments. Our partnership will ensure that this data becomes more accessible than ever to businesses around the world.”

Visilion, Sony’s real-time cargo and asset tracking solution, offers industry-leading shock, tilt and temperature detection capabilities, among others, to ensure that goods are handled properly and maintained at the right temperature and humidity during transit, thereby mitigating losses. This functionality, combined with FourKites’ market-leading Dynamic ETA® across all modes, provides shippers with complete visibility into potential disruptions and product loss for goods in transit. In addition, FourKites’ international tracking capabilities, together with Visilion sensor data, provide an added dimension of granular visibility into ocean containers that often move through complicated, multi-stop journeys.

“FourKites’ shared commitment to industry-leading innovation, product quality and industry collaboration made them the obvious partner for us,” said Erik Lund, Head of Tracking Division, Sony Network Communications Europe. “We look forward to working together to provide our mutual customers with integrated supply chain data to fuel better decision-making and, ultimately, more efficient supply chain operations — in Europe and around the world.”

Over the last year, FourKites has experienced record growth in the European, Middle Eastern and African (EMEA) markets, achieving 97% growth in shipments YoY as of October 2022. The number of customers tracking loads with FourKites in EMEA grew 40% in the same time period, while the number of carriers tracking shipments grew by 50% in the same period.

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 210 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release

Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release

Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye